$Accolade (ACCD.US)$
Healthcare Tech Transformation: How Transcarent and Accolade's Merger Reshapes Patient Care

$Accolade (ACCD.US)$ Accolade Agrees to Be Acquired, Brought Private by Transcarent in $621 ( $7.03 per share)

$Accolade (ACCD.US)$ 🚀🚀🚀

$Accolade (ACCD.US)$
Accolade Announces Results for Fiscal Second Quarter 2025
Accolade (NASDAQ: ACCD) announced financial results for fiscal Q2 2025 ended August 31, 2024. Revenue increased 10% to $106.4 million, while net loss improved 27% to $23.9 million. Non-GAAP Adjusted EBITDA loss narrowed 68% to $2.8 million, and Adjusted Gross Margin expanded to 47.3%.
CEO Rajeev Singh stated that Accolade is positioned to deliver its first full year of Adjusted EBITDA profitability and positiv...

$Accolade (ACCD.US)$ lol now competition to cut target price.